Solicitation of Nominations for Appointment to the Clinical Laboratory Improvement Advisory Committee (CLIAC), 68172 [2019-26921]

Agencies

• Centers for Disease Control and Prevention
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 84, Number 240 (Friday, December 13, 2019)]
[Notices]
[Page 68172]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-26921]



[[Page 68172]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Solicitation of Nominations for Appointment to the Clinical 
Laboratory Improvement Advisory Committee (CLIAC)

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) is 
seeking nominations for membership on CLIAC. CLIAC, consisting of 20 
members including the Chair, represents a diverse membership across 
laboratory specialties, professional roles (laboratory management, 
technical specialists, physicians, nurses) and practice settings 
(academic, clinical, public health), and includes a consumer 
representative. In addition, the Committee includes three ex officio 
members (or designees), including the Director, CDC; the Administrator, 
Centers for Medicare and Medicaid Services (CMS); and the Commissioner, 
Food and Drug Administration (FDA). A nonvoting representative from the 
Advanced Medical Technology Association (AdvaMed) serves as the 
industry liaison. The Designated Federal Officer or their designee and 
the Executive Secretary are present at all meetings to ensure meetings 
are within applicable statutory, regulatory and HHS General 
Administration manual directives.

DATES: Nominations for membership on CLIAC must be received no later 
than March 1, 2020. Packages received after this time will not be 
considered for the current membership cycle.

ADDRESSES: All nominations should be mailed to Nancy Anderson, MMSc, 
MT(ASCP), CLIAC Secretary, Senior Advisor for Clinical Laboratories, 
Division of Laboratory Systems, Center for Surveillance, Epidemiology 
and Laboratory Services, Office of Public Health Scientific Services, 
Centers for Disease Control and Prevention, 1600 Clifton Road NE, 
Mailstop V24-3, Atlanta, Georgia 30329-4027; telephone (404) 498-2741; 
or via email at [email protected] or faxed to (404) 471-2706.

FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Deputy Branch 
Chief, Quality and Safety Systems Branch, Division of Laboratory 
Systems, Center for Surveillance, Epidemiology and Laboratory Services, 
Office of Public Health Scientific Services, Centers for Disease 
Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, 
Georgia 30329-4027; telephone: (404) 498-2769; email: [email protected].

SUPPLEMENTARY INFORMATION: Nominations are being sought for individuals 
who have expertise and qualifications necessary to contribute to the 
accomplishments of the committee's objectives. Nominees will be 
selected based on expertise in the fields of microbiology (including 
bacteriology, mycobacteriology, mycology, parasitology, and virology), 
immunology (including histocompatibility), chemistry, hematology, 
pathology (including histopathology and cytology), or genetic testing 
(including cytogenetics); from representatives in the fields of medical 
technology, public health, and clinical practice; and from consumer 
representatives. Federal employees will not be considered for 
membership. Members may be invited to serve for up to four-year terms.
    Selection of members are based on candidates' qualifications to 
contribute to the accomplishment of CLIAC objectives (https://www.cdc.gov/cliac/).
    The U.S. Department of Health and Human Services policy stipulates 
that committee membership be balanced in terms of points of view 
represented, and the committee's function. Appointments shall be made 
without discrimination on the basis of age, race, ethnicity, gender, 
sexual orientation, gender identity, HIV status, disability, and 
cultural, religious, or socioeconomic status. Nominees must be U.S. 
citizens, and cannot be full-time employees of the U.S. Government. 
Current participation on federal workgroups or prior experience serving 
on a federal advisory committee does not disqualify a candidate; 
however, HHS policy is to avoid excessive individual service on 
advisory committees and multiple committee memberships. Committee 
members are Special Government Employees (SGEs), requiring the filing 
of financial disclosure reports at the beginning and annually during 
their terms. CDC reviews potential candidates for CLIAC membership each 
year and provides a slate of nominees for consideration to the 
Secretary of HHS for final selection. HHS notifies selected candidates 
of their appointment near the start of the term in July, or as soon as 
the HHS selection process is completed. Note that the need for 
different expertise varies from year to year and a candidate who is not 
selected in one year may be reconsidered in a subsequent year. SGE 
nominees must be U.S. citizens, and cannot be full-time employees of 
the U.S. Government. Candidates should submit the following items:
    [ssquf] Current curriculum vitae, including complete contact 
information (telephone numbers, mailing address, email address).
    [ssquf] At least one letter of recommendation from person(s) not 
employed by the U.S. Department of Health and Human Services. 
(Candidates may submit letter(s) from current HHS employees if they 
wish, but at least one letter must be submitted by a person not 
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
    Nominations may be submitted by the candidate him- or herself, or 
by the person/organization recommending the candidate.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities for both CDC and the Agency for Toxic Substances and Disease 
Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-26921 Filed 12-12-19; 8:45 am]
 BILLING CODE 4163-18-P